Cadent Therapeutics Acquired by Novartis for Up to $770 Million
By EsqSocial Corporation 22/12/20
Cadent Therapeutics, a Cambridge, Massachusetts-based, privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced on December 17, 2020, that Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics....
By: Rothwell, Figg, Ernst & Manbeck, P.C.